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Abstract: Several clinical reports indicate that the use of amphetaminic anorectic drugs or ergot
derivatives could cause valvular heart disease (VHD). We sought to investigate whether valvular
lesions develop in response to long-term oral administration of these drugs and to identify
drug-targeted biological processes that may lead to VHD. Treatment of New Zealand White rabbits
with pergolide, dexfenfluramine, or high-dose serotonin for 16 weeks induced valvular alterations
characterized by extracellular matrix remodeling. Transcriptome profiling of tricuspid valves
using RNA sequencing revealed distinct patterns of differentially expressed genes (DEGs) that
clustered according to the different treatments. Genes that were affected by the three treatments
were functionally enriched for reduced cell metabolism processes. The two drugs yielded more
changes in gene expression than serotonin and shared most of the DEGs. These DEGs were mostly
enriched for decreased biosynthetic processes, increased cell-matrix interaction, and cell response
to growth factors, including TGF-β, which was associated with p38 MAPK activation. Treatment
with pergolide specifically affected genes involved in homeostasis, which was corroborated by
the activation of the master regulator of cell energy homeostasis, AMPK-α, as well as decreased levels
of metabolism-related miR-107. Thus, both pergolide and dexfenfluramine may cause VHD through
valve metabolic reprogramming and matrix remodeling.
Keywords: serotonergic drugs; valvular heart disease; metabolism; rabbit model
1. Introduction
Valvular heart diseases (VHD) have been associated with the use of amphetaminic anorectic drugs,
including fenfluramine, benfluorex, and dexfenfluramine, and of ergot derivatives, such as those
used for the treatment of Parkinson disease, particularly pergolide and cabergoline [1–3]. However,
the mechanisms responsible for the development of drug-induced VHD have not been fully elucidated
yet. Animal studies have pointed to serotonin and its 5-HT2B receptor as a possible common pathogenic
link between drug-induced VHD and carcinoid heart valve diseases, characterized by excess of plasma
serotonin secreted by neuroendocrine tumors [4].
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Using a rabbit model, we previously showed that long-term oral administration of high-dose
serotonin causes VHD [5]. The tricuspid valve was affected with moderate to severe regurgitation
in all serotonin-treated rabbits, while left-sided aortic and mitral valves were less frequently and
severely involved. Histological examination indicated carcinoid-like plaques, thickened valves, and
chondroid metaplasia, confirming that serotonin signaling could be involved in the development of
VHD. However, whether this mechanism applies to the pathogenesis of other drug-induced VHD
remains undetermined.
Few studies in rodents have depicted a role of 5-HT2B receptors in valvular alterations induced
by pergolide or amphetaminic anorectic drugs. The 5-HT2B receptor antagonist, cyproheptadine,
inhibited valvular toxicity triggered by long-term intraperitoneal injections of pergolide in rats [6].
Importantly, a recent study in mice indicated that valve remodeling induced by chronic infusion
of nordexfenfluramine, the main metabolite of dexfenfluramine and benfluorex, occurred through
a direct stimulation of 5-HT2B receptors by this drug metabolite, independently of an increase in
free serotonin [7]. Indeed, 5-HT2B receptors blockage by antagonists or its deficiency in transgenic
Htr2B-/- mice prevented nordexfenfluramine-induced valve lesions, whereas depletion of serotonin by
tryptophan hydroxylase inhibitor para-chlorophenylalanine failed to do so.
Strikingly, it has been shown that drugs associated with VHD commonly display high affinity
for 5-HT2B receptors [8], while other drugs like phentermine or trazodone that lack such effects are
either low-affinity agonists or antagonists of the same receptor. Thus, drug interaction with serotonin
receptors might lead to VHD development through the activation of signaling pathways distinct from
those triggered by the natural agonist serotonin. Notably, it has been reported that specific microscopic
features can distinguish valve lesions induced by anorexigen exposure from those associated with
rheumatic disease, floppy mitral valve syndrome, or carcinoid heart diseases [9].
We therefore hypothesized that different pathological mechanisms may underly the adverse
valvular effects of amphetaminic anorectic drugs, ergot derivatives, and high-dose serotonin. Our
study aimed at investigating the mechanisms of these drug-induced VHDs using a rabbit model of
chronic oral administration of dexfenfluramine or pergolide, versus serotonin.
2. Results
2.1. Oral Serotonin, Pergolide, and Dexfenfluramine Cause Valvular Lesions with Distinct Histological
Features
Sixteen-week administration of pergolide (0.5 mg/kg per day) or dexfenfluramine (10 mg/kg
per day) in drinking water of adult female rabbits did not affect behavior or modify body weight as
compared to non-treated or serotonin-treated (80 mg/kg per day) rabbits. The weight of explanted
heart and ratio of heart to body weight remained unchanged. At the end of the procedure, pergolide
and dexfenfluramine were detected in rabbit plasma, with concentrations equal to 0.074 ± 0.038 ng/mL
and 2.08 ± 1.09 ng/mL, respectively.
Both treatments led to the development of histological alterations of aortic, mitral, and tricuspid
valves (Figure 1). Serotonin (Figure 1B,U) and pergolide induced the formation of chondroid
metaplasia in aortic hinge of all rabbits (Figure 1C,U) (p = 0.05), while it occurred in two rabbits
out of three after dexfenfluramine treatment (Figure 1D,U) (p = 0.2). Pergolide led to aortic leaflet
thickening (Figure 1V), with accumulation of glycosaminoglycan (GAG)-rich deposits in leaflets of
the three valves (Figure 1G,K,O). GAG deposits were also observed in response to serotonin treatment
(Figure 1F,J,N). The tricuspid valve (TV) leaflets of dexfenfluramine-treated rabbits were characterized
by abundant disorganized collagen fibers and less GAG (Figure 1P,T). TV leaflets of pergolide- and
dexfenfluramine-treated rabbits showed areas of connective tissue growth factor (CTGF) that were
not observed in the serotonin-treated group (Supplementary Material online, Figure S1A). None of
the treatments induced calcification or infiltration of macrophages (Supplementary Material online,
Figure S1B) in valve leaflets. Thus, these histological observations indicate that oral administration of
pergolide, dexfenfluramine, or serotonin all caused valvular lesions.
Int. J. Mol. Sci. 2020, 21, 4003 3 of 15
Figure 1. Drug treatments induce distinct valvular lesions: (A–D): Representative Movat’s pentachrome
staining performed on heart section from control (A) and serotonin- (B), pergolide- (C), and
dexfenfluramine- (D) treated rabbits. Arrowheads indicate chondroid metaplasia. (E–P): Representative
Movat’s pentachrome staining performed on aortic valve (AoV) (E-H), mitral valve (MV) (I–L), and
tricuspid valve (TV) (M–P) leaflet sections from control (E,I,M), serotonin (F,J,N), pergolide (G,K,O),
and dexfenfluramine (H,L,P). Arrowheads indicate GAG-rich deposit. (Q–T): Picrosirius red staining
performed on TV leaflet section from control (Q) and serotonin- (R), pergolide- (S), and dexfenfluramine-
(T) treated rabbits. Arrowhead indicates remodeled collagen layer. (U): Percentage of hearts displaying
chondroid metaplasia at the aortic valve hinge. (V–X): Leaflet area was measured and averaged from
at least 4 different sections per valve and rabbit (n = 3). Data are reported as dot plots where each dot
represents a rabbit and the horizontal bar indicates the mean ±SEM. * p < 0.05. Kruskal–Wallis test was
used to determine statistical significance (n = 3). C = control, S = Serotonin, P = Pergolide, and D =
Dexfenfluramine. Scale bars = 200 µm.
2.2. RNA Profiling Identifies Gene Expression Patterns of Drug-Induced Valvular Alterations
In order to further characterize differences of valvular alterations induced by the two drugs and
serotonin, we used an unbiased RNA-sequencing approach to identify differentially regulated genes in
tricuspid valves isolated from the three treatment groups compared to non-treated rabbits.
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Principal component analysis identified subgroups of individuals based on treatment (Figure 2A).
Moreover, hierarchical clustering of differentially expressed genes (DEGs) identified four clusters of
distinct expression patterns that corresponded to different treatments (Figure 2B). In terms of numbers
of DEGs per treatment (including both protein-coding and non-coding RNA species), pergolide and
dexfenfluramine modified the expression of 2692 and 3020 genes, respectively, whereas only 533 genes
were altered by serotonin. As shown on the Venn diagram of Figure 2C, pergolide and dexfenfluramine
shared a majority of DEGs (up to 78%), consistent with PCA and hierarchical clustering analysis, while
only about 30% of genes (169 genes) modified in response to serotonin were common to drug treatments.
Full lists of DEGs for all comparisons are provided in Supplementary Material online (Table S1). These
first analyses indicated that the two drugs induced more similar RNA profile modifications than
serotonin did.
Figure 2. RNA-seq analysis of tricuspid valve (TV) transcriptomes indicate that Pergolide and
Dexfenfluramine treatment shares the majority of differentially expressed genes (DEGs). (A): Principal
component analysis (PCA) on tricuspid valve leaflets treated with water (green dots, n = 5), serotonin
(orange dots, n = 5), pergolide (purple dots, n = 5), and dexfenfluramine (pink dots, n = 5). (B):
Heatmap view of z-scored expression profile of DEGs in TV of rabbits treated with serotonin (n = 5),
pergolide (n = 5), and dexfenfluramine (n = 5) compared to control (n = 5). (C): Venn diagram displays
comparison between DEGs for each drug treatment. (D): Data of qRT-PCR (n = 5 per treatment) are
reported as dot plots where each dot represents a rabbit and the horizontal bar indicates the mean
±SEM as compared to relative fold change obtained by RNA-seq analysis. # FDR <0.05, * p < 0.05
determined with one-way ANOVA followed by Dunnett’s multiple comparison test (n = 5 for each
treatment). ˆ <0.05 determined with Mann–Whitney test.
RT-qPCR analyses were performed to validate our RNA-seq data (Figure 2D). Both techniques
demonstrated the upregulation of COL1A2, and MGP, encoding collagen type I α2 chain and Matrix
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Gla protein, respectively, in response to the three treatments, upregulation of the ribosomal protein
L11 gene RPL11 by serotonin, upregulation of HAPLN1 encoding Hyaluronan And Proteoglycan Link
Protein 1 by dexfenfluramine, and downregulation of miR-107 in response to pergolide.
2.3. Gene Ontology Analyses Depict Enrichment of Distinct Biological Processes Leading to Valve Remodeling
To determine the biological functions associated with DEGs changes induced by the two drugs
and serotonin, Gene Ontology (GO) analysis was performed. Lists of DEGs common to all treatments
(165 genes), to the two drugs (1927 genes), and specific to each of the treatments (serotonin: 273
genes; pergolide: 572 genes; dexfenfluramine: 862 genes) were separately considered for the analysis
(Figure 2C). Figure 3A visualized the biological processes (GO terms) enriched by the three treatments
as well as some genes associated with one or more GO terms. The biological processes included cell
respiration, glucose, fatty acid, and nucleotide metabolic processes, along with response to oxygen
levels and muscle structure development. More specific trends in GO terms were shown in Figure 3B,
indicating that the three treatments modified the expression of genes that mostly contributed to
a decrease of these processes that were all related to cell metabolism. In accordance with this result, we
observed an increase of phosphorylation of the central energy sensor AMP-activated protein kinase-α
(AMPK-α) on residue Thr172, which reached statistical significance in response to serotonin and
pergolide (p < 0.05) as compared to non-treated rabbit valves (Figure 3C).
Figure 3. Decreased metabolism and muscle structure are enriched by serotonin, pergolide, and
dexfenfluramine treatment. AMPK activation by serotonin and pergolide. (A): Chord plot shows 46
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common DEGs and their overlap between significant Gene Ontology (GO) terms. (B): Circular plot is
colored according to z-score and highlights logFC of DEGs among significant GO terms. The outer
circle shows a scatter plot for each term of the logFC of the assigned genes. Red and blue dots display
individual up-regulated and down-regulated genes, respectively. The inner rectangles are sized to
positively correlate with the significance of each GO term, and colored to represent the overall direction
of change in expression of each individual term. (C): Western blotting detection of phosphorylation of
AMPKα and total AMPKα in TV leaflet total protein extracts. Data are reported as dot plots where
each dot represents a rabbit and the horizontal bar indicates the mean ±SEM. * p < 0.05, determined
with one-way ANOVA followed by Dunnett’s multiple comparison test (n = 5 for each treatment).
The 1927 genes that were modified by pergolide and dexfenfluramine were enriched for decreased
RNA processing, ribonucleoprotein complex biogenesis, and gene expression (Figure 4A,B). The two
drugs also provoked an enrichment of genes involved in cell response to growth factors, including
TGF-β, cell-matrix adhesion, collagen fibril organization, and blood vessel development. We thus
determined whether treatments with the two drugs and serotonin would differentially trigger
the activation of MAPK pathways. The p38 MAPK pathway is indeed activated downstream of
TGF-β receptors and is required for TGF-β-induced myofibroblastic activation of valvular interstitial
cells (VICs) [10]. While ERK phosphorylation was only induced by serotonin treatment (Figure 4C),
we found significantly elevated p38 MAPK phosphorylation in valves of rabbits treated with pergolide
that was also marginally induced by dexfenfluramine but not with serotonin.
Figure 4. Pergolide and dexfenfluramine treatment promote a decrease in biosynthetic process and
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an increase of response to growth factor stimulation: (A): Chord plot indicates common DEGs for
pergolide and dexfenfluramine with at least a 2-fold change compared to control tricuspid leaflets and
related to significant GO terms. (B): Circular plot indicates GO terms that are likely to be decreased or
increased by pergolide and dexfenfluramine. (C): Western blotting detection of phosphorylated ERK
(p-ERK), total ERK, phosphorylated p38 (p-p38), and total p38 in TV leaflet total protein extracts. Data
are reported as dot plots, where each dot represents a rabbit and the horizontal bar indicates the mean
± SEM. * p < 0.05, determined with one-way ANOVA followed by Dunnett’s multiple comparison test
(n = 5 for each treatment).
We then searched for biological processes that would distinguish each treatment (Figure 5A–F).
It appeared that, in sharp contrast to the two drugs together, serotonin caused an increase of
ribonucleoprotein complex biogenesis, gene expression, and RNA processing (Figure 4A,B and
Figure 5A,B). In agreement with the strong activation of AMPK-α, pergolide specifically affected
genes promoting homeostatic process, and, to a lesser extent, organ growth (Figure 5C,D). Finally,
dexfenfluramine treatment increased cytoskeletal organization and tissue morphogenesis (Figure 5E,F),
which might corroborate the observed distinct changes induced on valve histology (Figure 1). Altogether,
these results indicated that high-dose serotonin, pergolide, and dexfenfluramine cause valve remodeling
through distinct molecular pathways and biological processes.
Figure 5. Enrichment of specific biological processes by each treatment. (A): Chord plot indicates
specific DEGs for serotonin treatment with at least a 1.5-fold change compared to control tricuspid
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leaflets related to significant GO terms. (B): Circular plot indicates GO terms that are likely to be
increased by serotonin. (C): Chord plot indicates specific DEGs for serotonin treatment with at least
a 1.6-fold change compared to control tricuspid leaflets related to significant GO terms. (D): Circular
plot indicates GO terms that are likely to be increased by pergolide. (E): Chord plot indicates specific
DEGs for dexfenfluramine treatment with at least a 1.5-fold change compared to control tricuspid
leaflets related to significant GO terms. (F): Circular plot indicate GO terms that are likely to be
increased by dexfenfluramine.
3. Discussion
Our study is the first in vivo demonstration of adverse heart valve alterations induced by chronic
oral administration of either an amphetaminic anorectic drug, dexfenfluramine, or an ergot derivative,
pergolide. We uncovered a novel mechanism of drug-induced VHD relying on disruption of cell
metabolism and associated extracellular matrix (ECM) remodeling.
A comparison of the effects of these drugs with those of a high dose of serotonin indicated that
the mechanisms leading to valve lesions are likely to differ. Indeed, the three treatments yielded
distinct valve histology modifications, signaling pathway activation, and differential changes in RNA
profiles. Nevertheless, as proposed earlier [3,6,7], we could not exclude that the drugs might exert their
effect by interacting with serotonin receptors. It is possible that the drugs might exhibit higher affinity
for 5-HT2B receptors than serotonin, thereby triggering differential cell responses [8]. The identity of
the valve receptors mediating the drug effects remains to be investigated.
We also found that these treatments caused distinguished histological lesions with different
ECM reorganization. Valve leaflets display a complex, multi-layered ECM structure that provides
strength, flexibility, and resistance to bending and tensile stretch. ECM turnover is tightly regulated
by VICs, the major cell type of the valves. Under pathological conditions, transition of VIC to an
activated state enhances ECM synthesis and degradation [11,12]. Dysregulation of ECM turnover,
i.e., ECM remodeling, is therefore a major contributor to leaflet dysfunction and VHD [13]. Our
finding that dexfenfluramine led to distinct ECM remodeling as compared to serotonin is in agreement
with a previous study on human pathological valves showing distinctive microscopic valve features
after amphetaminic anorectic exposure compared to carcinoid heart diseases [9]. We observed that
pergolide and serotonin resulted in higher GAG content, while dexfenfluramine led to accumulation of
disorganized collagen fibers and less GAG. As observed in myxomatous mitral valve degeneration [14],
high GAG content is known to contribute to leaflet weakening and valve prolapse, while collagen
accumulation with less GAG is associated with leaflet stiffening as in rheumatic mitral stenosis.
In line with these observations, our RNA-seq data depicted that the two drugs, in contrast to
serotonin, promoted cell responses to TGF-β and activated p38 MAPK. Notably, TGF-β-mediated p38
MAPK activation plays a key role in VIC transition to an activated state, and subsequent fibrosis [10,15].
Overall, our RNA profiling revealed differential changes in RNA expression patterns in response to
the two drugs and serotonin. First, the number of DEGs was much higher upon drug treatment than
with serotonin. Second, the two drugs shared up to 75% of DEGs, while only 5–6% of DEGs were
shared with serotonin. More importantly, our data pointed out distinct biological processes triggered
by the three treatments. Interestingly, the two drugs were found to slow down the valve biosynthetic
process. In particular, pergolide promoted the homeostatic biological process.
Despite the recognized importance of valvular cell biology in the pathogenesis of VHD, there is
a paucity of information regarding the metabolism of heart valves. However, the metabolic syndrome
has long been associated with VHD such as calcific aortic stenosis, suggesting that cardiometabolic risk
factors could actively participate in the pathophysiology of aortic valve disease [16]. Furthermore, it
has been shown in mouse models that hyperglycemia and mild hyperlipidemia can induce aortic valve
disease [17]. An in vitro study using porcine VICs provided a direct link between cell metabolism and
cell-matrix interaction [18]. This study showed that an alteration in metabolic substrate availability
could affect valvular phenotypic properties such as contractility, as shown in a collagen gel contraction
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assay. The authors proposed that persistent hyperglycemia could lead to valvulopathy through
pathological collagen remodeling. Our study goes a step further by strongly suggesting that metabolism
disturbance induced by serotonergic drugs like pergolide and dexfenfluramine may lead to valve
disease through valve metabolic reprogramming and subsequent ECM remodeling. The fact that
the two drugs led to a significant increase in cell-matrix adhesion further supports the existence of
a link between cell metabolism and cell-mediated ECM remodeling [19]. As a general rule, energy and
nutrient availability dictate the level and type of biosynthesis in the cell, including the synthesis of
ECM, integrin-dependent cell–ECM interactions, and the amount of energy available to maintain cell
viability and undergo cytoskeletal remodeling [20]. It is therefore noteworthy that genes modified
by dexfenfluramine were enriched for cytoskeletal organization process. Furthermore, changes
in cytoskeleton organization may promote VHD. For instance, RhoA signaling drives heart valve
calcification [21], and mutations in Flna [22] and Dchs1 [23] encoding a cadherin and a cytoskeleton
protein involved in mechanotransduction, respectively, both lead to the development of myxomatous
valve disease. Strikingly, VIC elongation that occurs under hypertensive conditions was associated
with altered cell metabolism [24].
The impact of pergolide on valve metabolism was corroborated by a significant activation of
the master regulator of cell energy homeostasis AMPK-α [25]. Once activated, AMPK triggers a switch
from ATP-consuming anabolic pathways to ATP-generating catabolic pathways in order to preserve
energy homeostasis. Biosynthetic processes, such as gluconeogenesis, glycogen synthesis, lipogenesis,
cholesterol synthesis, and protein synthesis are inhibited, whereas glucose utilization, fatty acid
oxidation, and mitochondrial biogenesis are stimulated. These pathways are dysregulated in obese
patients presenting metabolic syndrome associated with diabetes, lipid abnormalities, and energy
imbalances. In this context, AMPK has been an attractive drug target to manage lipid and glucose
abnormalities and maintain energy homeostasis, alleviating cellular dysfunction in various cardiac
diseases [26]. Our finding that pergolide, similarly to serotonin, activates AMPK is remarkable knowing
that the role of this kinase in heart valve homeostasis was, until now, totally unknown.
In agreement with the effect of pergolide on valve metabolism, this drug also significantly reduced
valvular miR-107 levels, a key regulator of the process of metabolic reprogramming [27], mainly
controlling glycolysis. miR-107 was reported to be upregulated in obese mice, and its silencing
improved glucose homeostasis and insulin sensitivity [27]. The role of miR-107 in VHD has never
been investigated.
Few studies have analyzed valve transcriptomic profiles by RNA-seq and mostly focused on
calcified bicuspid and tricuspid aortic valves [28,29]. These studies highlighted main active biological
processes leading to abnormal leaflet architectural organization, alteration of ECM constituents, and
valvular remodeling. For instance, the study by Guauque-Olarte et al. [28] showed an enrichment
for genes involved in fibrosis in diseased aortic valves versus normal ones, thereby suggesting that
matrix remodeling could represent an interesting therapeutic target. This is strikingly similar to our
findings with the two drugs. Indeed, biological processes such as response to TGF-ß, regulation of
cell death, and cellular response to growth factors that are affected by the two drugs all represent
mechanisms leading to fibrosis. To our knowledge, no other studies investigated RNA expression
profiles in diseased tricuspid valves nor drug-induced modifications of valvular RNA. Thus, our
study shows for the first time that serotoninergic drugs disrupt the normal valve homeostatic process,
through biological processes that have been associated with degenerative aortic valve calcification.
Taken together, our data indicate that long-term use of pergolide or dexfenfluramine causes VHD
through distinct molecular mechanisms resulting in valve metabolic reprogramming (Figure 6). Besides
activation of p38 MAPK signaling, pergolide targets AMPK- and miR-107-dependent homeostasis
processes, and dexfenfluramine affects cytoskeletal organization. Drug-induced alterations of valve
homeostasis and/or cytoskeleton may modify valvular cell–ECM interactions, leading to ECM
remodeling and subsequent valvulopathy.
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Figure 6. Schematic summary: chronic use of pergolide or dexfenfluramine activates p38 MAPK
in valvular cells. Specifically, pergolide triggers AMPK- and miR-107-dependent homeostasis
processes, whereas dexfenfluramine affects cytoskeletal organization. Drug-induced alterations
of valve homeostasis and cytoskeleton are associated with net inhibition of biosynthetic processes that
reflect valve metabolic reprogramming, leading to ECM remodeling and valvulopathy. Gray arrows
represent hypothetical links.
Further investigations should determine whether antagonists of 5-HT2B receptors could reverse
pergolide or dexfenfluramine effects or whether targeting the identified pathways could prevent
drug-induced valve remodeling. The evaluation of valvular effects of serotonergic drugs could also be
clinically relevant. More generally, our findings highlight a need for improving our understanding of
the link between metabolism and valvular heart disease, with the aim to identify new treatments of
these diseases, along with valvulo-metabolic risk factors, as part of the cardiometabolic risk assessment.
4. Materials and Methods
4.1. Rabbits
Thirty-two 8-week female New Zealand white rabbits (Crl:KBL) (2–2.5 Kg) were divided into
4 groups (n = 8) based on drug treatment: serotonin (80 mg/kg/day), pergolide (0.5 mg/kg/day) [6],
dexfenfluramine (20 mg/kg/day) [7], and non-treated controls. Drugs were administered via drinking
water. Body weight was determined weekly throughout the protocol. After 16 weeks, blood samples
were taken via catheterized marginal ear vein under general anesthesia (intramuscular injection of
droperidol (0.625 mg/kg), and of a mixture of xylasine (5 mg/kg), and ketamine (35 mg/kg)). Adequacy
of anesthesia was monitored by palpebral and pedal withdrawal reflex. They were then euthanized by
intra-cardiac injection of sodium pentobarbital (200 mg/kg) before collection of heart tissues. All rabbit
experiments are approved by our institutional ethics review board (Ethics Committee of the University
of Liege, Belgium) and conform to the guidelines from Directive 2010/63/EU of the European Parliament
on the protection of animals used for scientific purposes.
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4.2. Measurements of Pergolide and Dexfenfluramine in Rabbit Plasma
Dexfenfluramine and pergolide concentrations in rabbit serum were determined by liquid
chromatography coupled with mass spectrometry (LC–Chip–MS/MS). Briefly, the chromatographic
separation was achieved on a 1200 series LC-chip system (Agilent Technologies, Germany) using
an Ultra High Capacity chip including a 500 nL trapping column and a 150 mm × 75 µm analytical
column, both packed with a Zorbax 80SB 5 µm C18 phase (Agilent Technologies). The mobile phase
was composed of H2O/FA (100:0.1, v/v) (A) and ACN/H2O/FA (90:10:0.1, v/v/v) (B) and used in gradient
elution mode (from 15% to 69% B in 5 min). Mass spectrometric detection was performed using a 6340
Ion Trap equipped with a nanoelectrospray ionization source operating in positive mode (Agilent
Technologies, Waldbronn) (transitions followed for dexfenfluramine: 232.0 −> 158.8; 186.8 m/z and for
pergolide: 315.2 −> 207.9; 267.0 m/z). Finally, an Oasis µElution MCX 96-well plate (Waters, UK) was
used to prepare the samples for the analysis. Fifty microliters of plasma was needed per experiment
and all conditions were performed in duplicate and back-calculated using a calibration curve.
4.3. Histology and Immunohistochemistry
Rabbit hearts (n = 3 per treatment) were harvested after 16 weeks of treatment. Hearts were
fixed in 4% paraformaldehyde, dehydrated through a graded ethanol series, cleared in xylene, and
embedded in paraffin. Rabbit hearts were sectioned at 7 µm. Movat’s pentachrome staining (American
MasterTech) and Picrosirius red staining (Sigma-aldrich) of tissue sections were performed according
to manufacturer’s instructions. Heart valve leaflet area was measured from 4 to 10 different tissue
sections and averaged. For RAM11 staining, slides were pretreated for 30 min using citric acid antigen
retrieval in water bath at 96 ◦C. The primary antibodies used were RAM11 (Dako) and anti-rabbit
CTGF (Abcam) antibodies. Slides were counterstained for 2min with hematoxylin-eosin. Images were
captured using Olympus FSX100.
4.4. RNA Isolation
Tricuspid heart valves (n = 5 per treatment) were dissected and collected separately after 16 weeks
of treatment. Valve tissues were snap-frozen in liquid nitrogen before being stored at −80 ◦C until
RNA extraction. Total RNA was extracted using the miRNeasy Mini Kit (Qiagen).
4.5. RNA Sequencing, Data Processing, and Analysis
RNA integrity was verified on a Bioanalyser 2100 with RNA 6000 Nano chips (Agilent
technologies, CA, USA). DV200 values, calculated from Bioanalyser traces, were comprised between
55% and 73% and did not differ between experimental groups. After ribosomal RNA depletion
using the RiboGoneTM - Mammalian rRNA depletion kit (Clontech, CA, USA), libraries were
prepared using the SMARTer®Stranded RNA-Seq Kit (Clontech, CA, USA) following manufacturer’s
instructions. Libraries were validated on a Bioanalyser DNA 1000 chip and quantified by qPCR
using the KAPA library quantification kit. Sequencing of multiplexed libraries was performed
on an Illumina NextSeq500 sequencer generating a total of around 10 million mapped reads per
library on average. Raw reads were first demultiplexed and adapter-trimmed using Illumina
bcl2fastq conversion software v2.17; then, the first three nucleotides of each read (added during
the SMARTer®protocol) were removed using the FATSX Toolkit (v0.0.13). After quality control with
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), reads were aligned to the rabbit
oryCun2 reference genome using Tophat v2.1.1 [30]. Reads were first aligned to a virtual transcriptome
generated based on the annotation gene models, and then reads that did not fully map were aligned
to the genome, spliced as needed. Quality of the sequencing data was controlled using Picard tools
(http://broadinstitute.github.io/picard/). For the differential expression analysis at the gene level, raw
gene counts were generated using HTseq count in “union” mode [31].
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Independent filtering was done to remove uninformative genes. The proposed filtering method
was applied in the HTSFilter package within the Bioconductor package in R (limma: Linear Models for
Microarray and RNA-Seq Data User’s Guide) [32]. Prior to differential analysis, unwanted variations
were identified using the svaseq () and RUVr () functions in R Bioconductor package RUVSeq [33]. From
23,669 detectable ENSEMBL genes, differentially expressed genes (DEGs) between treatment groups
and controls were identified using limma-voom method from the Bioconductor/R package limma, using
empirical Bayes statistical methods. A gene is considered differentially expressed if its corresponding
FDR is less than 5%. Multiple comparison was handled by Benjamini–Hochberg approach. The RNAseq
data have been deposited in NCBI’s Gene Expression Omnibus and are accessible through GEO Series
accession number GSE113082 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113082).
4.6. Gene Enrichment Analysis
Common or specific differentially expressed genes with an FDR < 0.05 were functionally annotated
by using Database for Annotation, Visualization, and Integrated Discovery (DAVID version 6.8),
and filtered out with database GOTERM_BP_FAT. Gene ontology (GO) Biological Processes with
a Benjamini–Hochberg FDR-adjusted p-value < 0.05 were selected. Visualization of GO terms was
performed using the GOPlot R package and GOCircle and GOChord function.
4.7. Real-Time Quantitative PCR
Total RNA extracted from rabbit tricuspid valves was reverse transcribed into cDNA using
RevertAid H Minus First Strand cDNA Synthesis kit (Thermo Fisher Scientific) according to
manufacturer’s instructions. Quantitative real-time PCR analyses were performed using SYBR
PCR mix (Takara). Primer sequences can be found in Supplementary Material online (Table S2).
Changes in gene expression were calculated by ∆∆Ct method using SNORA63 for normalization.
The average of control samples was then set to 1 for each gene.
4.8. Protein Extraction and Western Blotting
Proteins were isolated from the organic phenol phase of QIAzol reagent-treated valvular tissues
according to manufacturer’s protocol (Qiagen). Western blotting was performed according to classical
procedures using the following primary antibodies purchased from Cell Signalling: phospho-p38 MAPK
(Thr180-Tyr182), p38, phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), Erk1/2, phospho-AMPKα
(Thr172), AMPKα. Blots were analyzed with ImageStudio software (LI-COR).
4.9. Statistics
Data normality was assessed using the quantile–quantile plot and histogram of error terms.
Departure from normality was handled either by log transformation or non-parametric approach.
Multiple comparisons between treated rabbits and controls were done using one-way ANOVA
or Kruskal–Wallis test followed by Dunnett’s post hoc test with control sample as the reference.
Comparison between two groups was performed using Mann–Whitney test. The appropriate statistical
test is mentioned in the figure legend. All statistical analyses were performed using SAS 9.4 (SAS
Institute Inc., Cary, NC, USA). Data are reported as dot plots, where each dot represents a rabbit and
the horizontal bar indicates the means ± SEM using PRISM5 software package (GraphPad). A p-value
< 0.05 was considered significant.
Supplementary Materials: The following Supplementary Materials are available online at http://www.mdpi.
com/1422-0067/21/11/4003/s1, Table S1: Full lists of DEGs in the different comparisons between the experimental
groups, Table S2: Sequences of primers used in qPCR assays, Figure S1: Immunhistochemical staining of CTGF
and macrophages in tricuspid valve leaflets of control and drug-treated rabbits.
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